Discover IRAK4 phosphoT345 monoclonal antibody from Abbomax

SAN JOSE, Calif. - Oct. 1, 2019 - PRLog -- AbboMax, Inc. offers IRAK4(pT345) monoclonal antibody. IRAK-4 (interleukin-1 receptor-associated kinase 4) is a serine/threonine protein kinase involved in the innate immune response. The protein contains three auto-phosphorylation sites. Out of these three phosphorylation sites, Threonine345 is the main prototypical phosphoresidue required for the activity of IRAK4 kinase. It is the primary phosphoresidue anchor toward the basic pocket that is conserved among kinases. This is why IRAK4(pT345) antibody is beneficial for cell signalling research.

IRAK4 functions upstream of IRAK1 and causes a cascade of phosphorylation events. It is recruited by MeD88 through TLR signalling, phosphorylates IRAK1, leading to the stimulation of nuclear factor κB (NF-κB), p38, and c-Jun N-terminal protein kinase mitogen-activated protein kinases (JNK MAPKs). The loss of IRAK4, or its intrinsic kinase activity, can stop signalling through these pathways. Deficiency in IRAK4 leads to impaired activation of the transcription factors NFκB, AP-1 and cJUN, and reduced production of inflammatory cytokines induced by signalling through TLRs.

The uncontrolled TLR/IL-1R signalling pathways, which involve IRAK4, lead to multiple diverse diseases ranging from chronic to autoinflammatory disorders. This protein is essential for most innate immune responses. IRAK-4 deficiency is an inherited disorder of the immune system (primary immunodeficiency). The most common infections in IRAK-4 deficiency are caused by the Streptococcus pneumoniae, Staphylococcus aureus, and Pseudomonas aeruginosa bacteria at a young age. Research also found that patients with melanin-cell tumors displayed an increase in the phosphorylation state of IRAK4.

Considering IRAK4's downstream position of the signalling events, it is an important drug therapy target for various inflammatory disorders including inflammatory bowel disease, rheumatoid arthritis, and other autoimmune diseases. IRAK4 may be a potential therapeutic drug target for systemic lupus erythematous (SLE).

AbboMax, Inc. (http://www.abbomax.com/) offers anti-IRAK4(pT345) monoclonal antibody. The company has been developing and manufacturing high performance immunoassay reagents for many years in California.  AbboMax specializes in high-quality custom service and products focusing on antibody and assay development, including polyclonal, phosphospecific antibodies, IHC grade monoclonal antibodies, FFPE cell pellets slides, tissue/cell blocks and CRO services.

By Natasha Raysberg, Ph.D.